[1-[(2,6-Diaminopurin-9-yl)methyl]-2-hydroxy-ethoxy]methylphosphonic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: [1-[(2,6-Diaminopurin-9-yl)methyl]-2-hydroxy-ethoxy]methylphosphonic acid
• 英文别名: [1-(2,6-diaminopurin-9-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
• 化学式: C₉H₁₅N₆O₅P
• 分子量: 318.23
• InChiKey: XGTJCNSZEASLLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  183
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• [EN] A PROCESS FOR THE PREPARATION OF (R)-9-[2-(PHOSPHONOMETH-OXY)PROPYL]ADENINE (PMPA)<br/>[FR] PROCÉDÉ DE PRÉPARATION DE (R)-9-[2-(PHOSPHONOMETH-OXY)PROPYL]ADENINE (PMPA)
  申请人：ITHEMBA PHARMACEUTICALS PROPRIETARY LTD

  公开号：WO2014033688A1

  公开（公告）日：2014-03-06

  This invention relates to a process for the preparation of (R)-9-[2- (phosphonometh-oxy)propyl]adenine (PMPA). This invention also relates to the preparation of Tenofovir disoproxil fumarate (TDF), a compound which can be produced from PMPA. The claimed process comprises reacting compound (6) with compound (7) in presence of 2,2,6,6- tetramethylpiperidinylmagnesium to compound (2), which is hydrolysed to (3).

  这项发明涉及一种制备(R)-9-[2-(磷酸甲氧基)丙基]腺嘌呤（PMPA）的过程。这项发明还涉及Tenofovir disoproxil fumarate（TDF）的制备，这是一种可以从PMPA生产的化合物。所述的过程包括在2,2,6,6-四甲基哌啶基镁的存在下，将化合物（6）与化合物（7）反应，得到化合物（2），然后水解为（3）。
• Lipid disulfide prodrugs and uses related thereto
  申请人：Emory University

  公开号：US10688112B2

  公开（公告）日：2020-06-23

  This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substitutents are disclosed herein.

  本公开涉及二硫化脂质原药，特别是二硫化脂质磷酸二酯核苷及其衍生物、药物组合物和相关用途。根据本公开的一个实施方案，提供了式 I 的化合物、 或其药学上可接受的盐或衍生物，其中的取代基已在本文中公开。
• Lipid Disulfide Prodrugs and Uses Related Thereto
  申请人：Emory University

  公开号：US20190015432A1

  公开（公告）日：2019-01-17

  This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substitutents are disclosed herein.